Previously untargetable, the KRAS G12D mutation—often found in never-smokers—is on the verge of becoming actionable. Emerging specific inhibitors like Zoldanrasib are showing high response rates (over 60%), suggesting a new targeted therapy option for a patient group that previously lacked one.

For years, the KRAS oncogene was considered a key cancer driver but impossible to target with drugs. Through resilient investigation, scientists recently developed effective therapies against it, proving that even long-held beliefs about 'undruggable' targets can be overturned with persistence.

Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

A new class of KRAS inhibitors targets the active 'on-state' of the protein, a departure from earlier drugs that targeted the inactive 'off-state'. These 'tri-complex inhibitors' use a chaperone protein to bind to the active GTP-bound KRAS, preventing downstream signaling and creating a new therapeutic avenue.

Instead of directly blocking the mutated KRAS protein, daraxin racid acts as a 'molecular glue.' It binds to a separate chaperone protein, and this new complex then disables the mutated KRAS protein. This indirect, novel mechanism of action is a breakthrough for targeting a protein that has been notoriously difficult to drug.

Faced with the 'undruggable' switch two pocket in KRAS, Blossom Hill modifies the drug's properties rather than the protein target. By engineering a molecule with 'pseudo irreversible' characteristics, they create a long-lasting effect that compensates for the challenging binding pocket, thereby enhancing in-vivo efficacy.

Unlike traditional small molecules that need a pocket on a target protein, molecular glues work by changing the surface of an E3 ligase. This modified surface then perfectly matches and binds the target protein, enabling its degradation without requiring a direct drug-to-target binding site.

Targeting the MYC cancer protein presents a dual challenge. Biologically, it's vital for healthy cells, creating a high risk of toxicity. Biophysically, its disordered, 'floppy' structure lacks the defined pockets that traditional drugs need to bind to, making it a 'holy grail' target.

Concarlo's technology was designed for p27, an intrinsically disordered protein (IDP) lacking a fixed structure. This same 'molecular glue' approach can be applied to other high-value but historically 'undruggable' IDP cancer targets, like p53 and MYC, creating a powerful drug discovery platform beyond their lead asset.